Incretin-based therapies offer a new approach for the management of type 2 diabetes, with a mechanism of action distinct from any existing class of glucose-lowering agents.
reference glucose-lowering agent, but head-to-head comparisons between two incretin-based therapies are scarce. Onetrial compared 1.8 mg liraglutide once daily with 10 µg exenatide twice daily, and showed greater efficacy and better tolerance with liraglutide.
2 2 mg exenatide (longacting release) once weekly was more effective and bettertolerated than 10 µg exenatide twice daily. 3 No long-term comparisons of GLP-1 receptor agonists with DPP-4 inhibitors have been published, except in abstract form. 4 Therefore evidence is lacking to clearly position GLP-1 receptor agonists versus DPP-4 inhibitors after failure to manage type 2 diabetes with metformin. 5 Thus Richard Pratley and colleagues' 26-week, randomised, parallel-group, open-label trial, 6 published in The Lancet today, is of great interest. Added to metformin, 1.2 mg and 1.8 mg liraglutide once daily significantly improved blood glucose control (change in HbA 1c from baseline: -1.24%, 95% Cl -1.37 to -1.11 for 1.2 mg; -1.50%, -1.63 to -1.37 for 1.8 mg) versus 100 mg sitagliptin once daily (-0.90%, -1.03 to -0.77; p<0.0001 for both comparisons). Furthermore, reductions in bodyweight were greater with 1.2 mg and 1.8 mg liraglutide (-2.86 kg, -3.39 to -2.32 for 1.2 mg; -3.38 kg, -3.91 to -2.84 for 1.8 mg) than with sitagliptin (-0.96 kg, -1.50 to -0.42; p<0.0001 for both comparisons). These results confirm previous reports of either liraglutide 2,7 or sitagliptin [8] [9] [10] in patients with type 2 diabetes that was not well controlled with diet and metformin. Further, similar findings were recorded with exenatide twice daily, 3, 11 exenatide (longacting release) once weekly, 2-4 and DPP-4 inhibitors vildagliptin 12 and saxagliptin 13 (table) .
Findings from today's study show the superiority of 1.8 mg versus 1.2 mg liraglutide for reduction of HbA 1c , butthis result has not been recorded in previous studies (table) . 7 Only the 1.8 mg dose of liraglutide was assessed in LEAD-6, 2 in which liraglutide once daily was shown to be superior to 10 µg exenatide twice daily for reduction of HbA 1c . Therefore 1.2 mg liraglutide should be considered as the starting dose in most patients with type 2 diabetes, with recommendations for titration up to 1.8 mg if target HbA 1c concentrations are not reached. However, no study has been published in which patients who were insufficiently controlled on 1.2 mg liraglutide had a significant improvement in glucose control from an increased dose of 1.8 mg liraglutide.
The superiority of liraglutide versus sitagliptin for blood glucose control and weight reduction was probably due to increased circulating concentrations of the GLP-1 agonist, leading to different pharmacological effects, as shown with exenatide.
14 Even though Pratley and colleagues recorded superior treatment satisfaction with 1.8 mg liraglutide than with sitagliptin, the gastrointestinal tolerance profile is better with sitagliptin than with liraglutide, and one pill of sitagliptin daily might be judged as easier to administer than one subcutaneous injection of liraglutide daily. The increased cost of liraglutide should be compared with the benefit provided by improved glucose control and weight reduction. Some important information is still unknown, but could help clinicians to choose the best incretin therapy to manage type 2 diabetes after failure with metformin. We do not know how the efficacy of GLP-1 receptor agonists versus DPP-4 inhibitors will vary long term during the progressive decline in β-cell function that is responsible for loss of glucose control, and the development and progression of chronic diabetic complications. Long-term safety also remains an open question. In our opinion, the range of type 2 diabetes is so heterogeneous that treatment probably needs to be tailored to individuals ratherthan strictly standardised. 5 Such an approach would need to take into consideration all biological, clinical, and psychosocial characteristics of every patient.
